Abstract: The image forming apparatus includes a current detection circuit for detecting an input current from the commercial power supply to the apparatus, in which: when a current detected by the current detection circuit exceeds a predetermined value, a maximum current suppliable to a fixing portion is restricted; and when a temperature of the fixing portion falls below, in a situation where the maximum current suppliable to the fixing portion is restricted, the predetermined temperature lower than a control target temperature, a conveyance interval of a recording material conveyed to the fixing portion is extended. In the image forming apparatus, even when a consumption current of the image forming apparatus is increased during successive image formation, it is capable of controlling the consumption current so as not to exceed a maximum current of a commercial power supply, securing desired fixability, and minimizing decline of image forming performance.

Abstract: The image forming apparatus includes a current detection circuit for detecting an input current from the commercial power supply to the apparatus, in which: when a current detected by the current detection circuit exceeds a predetermined value, a maximum current suppliable to a fixing portion is restricted; and when a temperature of the fixing portion falls below, in a situation where the maximum current suppliable to the fixing portion is restricted, the predetermined temperature lower than a control target temperature, a conveyance interval of a recording material conveyed to the fixing portion is extended. In the image forming apparatus, even when a consumption current of the image forming apparatus is increased during successive image formation, it is capable of controlling the consumption current so as not to exceed a maximum current of a commercial power supply, securing desired fixability, and minimizing decline of image forming performance.

Abstract: The present invention provides, as a pharmaceutical agent having an effect to inhibit the development and/or progression of liver cancer in hepatitis C virus-positive human cirrhosis patients, an agent for inhibiting the development and/or progression of liver cancer in hepatitis C virus-positive human cirrhosis patients, which contains three kinds of amino acids of isoleucine, leucine and valine.

Abstract: Severity of viral hepatitis type B in patients treated with an anti-viral agent including lamivudine is predicted on the basis of the quantified value of cytochrome c in body fluid of the patients. Cytochrome c is preferably quantified immunochemically.